Sign In
Buy ALPN
$64.97
+0 (+0%)
At Close: Aug 19, 2024
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
11:05am, Thursday, 02'nd May 2024
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alpine Immun
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN
07:50pm, Wednesday, 17'th Apr 2024
NEW YORK , April 17, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securi
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
03:43pm, Monday, 15'th Apr 2024
Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book
Could This Stock Be the Next Biotech Buyout?
05:29am, Saturday, 13'th Apr 2024
Vera Therapeutics is developing a dual-action antibody to treat kidney disorders, with successful results from the first portion of a pivotal study. Recently, Vertex Pharmaceuticals acquired Alpine Im
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alpine Immun
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
01:41pm, Friday, 12'th Apr 2024
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
2 Biotech Stocks Driving the Nasdaq Today
01:41pm, Thursday, 11'th Apr 2024
The Nasdaq is leading the charge today, with biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) up over 2% today.
Vertex Pharmaceuticals to Buy Alpine Immune in $4.9B Deal
10:46am, Thursday, 11'th Apr 2024
The acquisition is a bet on a drug under development to treat the kidney condition IgA nephropathy.
Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It
10:36am, Thursday, 11'th Apr 2024
Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed almost 21% on rumors of the deal.
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
09:47am, Thursday, 11'th Apr 2024
Drug maker Alpine Immune Sciences (NASDAQ: ALPN ) got a $4.9 billion buyout offer from Vertex Pharmaceuticals (NASDAQ: VRTX ) after getting good news on a new drug. Povetacicept, an autoimmune drug, w
Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)
09:23am, Thursday, 11'th Apr 2024
Alpine Immune Sciences Inc (NASDAQ: ALPN) is up 35% on Thursday after Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said it will acquire the biotechnology company for $65 per share. Is Alpine Imm
Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
08:06am, Thursday, 11'th Apr 2024
Vertex Pharmaceuticals Inc.'s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company's rare-disease franchise, analysts said Thursday.
Alpine Immune Sciences soars on $4.9bn Vertex takeover
07:16am, Thursday, 11'th Apr 2024
Alpine Immune Sciences Inc shares continued higher in pre-market trading, after soaring on Wednesday following news of the firm's US$4.9 billion takeover by Vertex Pharmaceuticals Incorporated. Shares
Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch
10:45pm, Wednesday, 10'th Apr 2024
Vertex Pharmaceuticals (VRTX) will acquire clinical-stage immunotherapy company Alpine Immune Sciences (ALPN) in a deal valued at around $4.9 billion, both companies said Wednesday.
